Latest From Biogen Inc.
Excessive pricing is once again under the spotlight In Europe. Consumer rights organizations in Belgium and Italy have referred Biogen to the national competition authorities over “exorbitant pricing.”
The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.
Fatality of healthy volunteer in early clinical trial prompts halt of all clinical work for candidate anti-epileptic, potentially hitting Eisai's product succession strategy in a core therapeutic area.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
- Gene Therapy, Cell Therapy
- Drug Delivery
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Biogen Idec Inc.
- Biogen Inc.
- Idec Pharmaceutical Corp.
- North America
- Parent & Subsidiaries
- Biogen Inc.
- Senior Management
Michel Vounatsos, CEO
Jeffrey Capello, EVP, CFO
Alfred W Sandrock, Jr., MD, PhD, EVP, CMO
Michael Ehlers, MD, PhD, EVP, R&D
Daniel Karp, EVP, Corp. Dev.
Chirfi Guindo, EVP & Head, Global Mktg.
- Contact Info
Phone: (617) 679-2000
225 Binney St.
Cambridge, MA 02142
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.